Volume three

Yelin Hu , in Encyclopedia of Tissue Engineering and Regenerative Medicine, 2019

Abstract

Healthcare reimbursement in the Us is a circuitous system that involves several stakeholders, almost notably healthcare providers, payers and beneficiaries. A manufacturer introducing a novel cell- or tissue-based therapy will face up challenges associated with obtaining reimbursement. This commodity describes the electric current landscape of reimbursement models in the United States, and examines existing policies for engineered products for a few of the major wellness insurance payers. It also discusses some issues that must be considered when an engineered product seeks to be paid through the healthcare reimbursement system. Information technology will identify some current issues that engineered products have encountered when they need to be reimbursed.

Read full affiliate

URL:

https://world wide web.sciencedirect.com/science/article/pii/B9780128012383655885

Settings of Intendance

Jean Marie. Carroll , ... Lorry R. Frankel , in Textbook of Interdisciplinary Pediatric Palliative Care, 2011

Reimbursement Issues

The reasons for woeful treatment of dying children and grieving families is due in large office to the healthcare organisation's inability to recognize the need for palliative care fifty-fifty when children are receiving curative intendance. 62

Reimbursement bug are a major obstacle to children and families receiving palliative care services for the post-obit reasons:

•

Criteria used to determine reimbursement for pediatric palliative care are only partly applicable to children,

•

Eligibility restrictions related to life expectancy frequently brand it difficult for families to choose palliative intendance for their children,

•

Unlike systems of payments between the government and private insurers affect both reimbursement and the types of services provided.

A significant bulwark is that state Medicaid hospice benefits are based on the federal Medicare model. Hospice eligibility criteria restrict care to individuals who will die within six months. Furthermore, concurrent treatment to prolong life cannot be pursued while receiving palliative care. Additionally, inside the 2010 regulations and reimbursement structure, families risk the loss of benefits such equally dietary supplements or skilled home nursing intendance if they have hospice. These criteria prevent families and clinicians from integrating both aspects of intendance. 63 It is too of import to note that private insurers model their hospice benefits along Medicare guidelines. There are multiple payers and financial sources for pediatric palliative intendance, versus i payer source, Medicare, for developed palliative intendance.

The Institute of Medicine report 1 states: "Approximately ii-thirds of children are covered by employment-based or other private health insurance; virtually i-fifth are covered by country Medicaid or other public programs, but some 14 to fifteen per centum of children under age 19 take no health insurance." Some of these uninsured children receive services based on safety-net providers, grants, or private donations. However, there remain children who do non receive necessary services. The IOM report further states that "for insured children and families, coverage limitations, provider payment methods and rules, and administrative practices tin discourage timely and full communication betwixt clinicians and families and restrict access to effective palliative and stop-of-life care."

The IOM report's recommendations are based on the premise that the hospice benefit exist restructured to ameliorate meet the needs of children. These recommendations include:

•

Elimination of eligibility restrictions related to life expectancy,

•

Elimination of the requirement to discontinue all curative treatment,

•

Add-on of an outlier payment category for children whose intendance is unusually costly.

The IOM too warns that the hospice healthcare delivery model for adults and children in 2010 tin can create "incentives for under treatment, overtreatment, inappropriate transitions between settings of care, inadequate coordination of care, and poor overall quality of care." three

In an effort to counterbalance the inequities created past the Medicare hospice model, Children's Hospice International (CHI) developed the Programme for All-Inclusive Treat Children (PACC) and their Families. This plan provides an alternative to the existing barriers regarding referral and reimbursement to obtaining palliative intendance for children. The PACC model is an innovative program, which provides access to intendance for all children diagnosed with life-threatening weather. It allows for reimbursement by all payers including private insurance, workplace coverage, managed care, and Medicaid. CHI PACC permits states to receive federal reimbursement for more coordinated services than are usually provided under Medicaid. 64

Congressional appropriations through the Centers for Medicare and Medicaid Services (CMS) initially funded pilot programs in Colorado, Florida, Kentucky, New York, New England, Utah, and Virginia. 64, 65 Florida and Colorado have been fully approved for CMS waivers. 65–67 Florida received its waiver approval in July 2005 for a v-twelvemonth, statewide demonstration project of the PACC program. 66 In January 2007, Colorado received approving of their request for a CMS waiver. They will implement a 3-year renewable demonstration project for pediatric palliative care. 67 Based on legislation mandated in the fall of 2006, California began a three-year pilot program in 2009 under the Children's Hospice and Palliative Care waiver. 68 Other states interested in implementing CHI PACC and are submitting requests for waivers include Arkansas, Illinois, Louisiana, Maryland, New United mexican states, Pennsylvania, Ohio, Tennessee, Texas, Utah, W Virginia, and the District of Columbia. 64 The myriad bug that surround reimbursement for palliative and end-of-life intendance, both for adults and children, are trigger topics for claiming and reform.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9781437702620000074

Edifice a Clinical CT Colonography Program

DAVID H. KIM Md , PERRY J. PICKHARDT MD , in CT Colonography: Principles and Practise of Virtual Colonoscopy, 2010

BILLING AND REIMBURSEMENT

Reimbursement for CTC is currently in a state of development and is apace irresolute (run into Affiliate 10). Currently, some diagnostic indications are broadly covered, although this varies somewhat from state to state. CTC for the purpose of screening is not nevertheless widely covered, but this should alter in the about future. The elective nature of CTC examinations allows for swell flexibility in scheduling and time to settle billing problems or questions prior to the functioning of the test. All examinations are thus typically preapproved. Information technology is helpful to have an individual skilled in this area to address the pertinent issues regarding reimbursement.

Read total chapter

URL:

https://www.sciencedirect.com/science/commodity/pii/B9781416061687000170

Outcomes Management

David W. CliftonJr. PT , in Concrete Rehabilitation'due south Office in Disability Management, 2005

Reimbursement

Reimbursement decisions both influence and are highly influenced by OM data. Outcomes measures are routinely considered when establishing the medical necessity, appropriateness, and reasonableness of care. Those rehabilitation modalities, techniques, and interventions not found to be efficacious and or cost-effective are potentially judged every bit non-reimbursable. Rehabilitation services that are covered may exist only those that are designed to achieve a clear functional goal and for which the demand for skilled professional services can exist clearly demonstrated through clinical documentation ( Clifton, 1995; Moorhead & Clifford, 1992; Steffen & Meyer, 1985).

Read total chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780721684741500192

Pharmaceutical Pricing and Reimbursement Regulation in Europe

T. Stargardt , S. Vandoros , in Encyclopedia of Wellness Economics, 2014

The Procedure of a Cost and Reimbursement Decision in the EU

Like to multitiered reimbursement lists (formularies) in the United states, many European countries operate so-chosen positive lists, i.e., lists containing all pharmaceuticals that are reimbursed upwards to a certain amount or for a certain percent of the pharmaceutical toll. The principal difference as compared with the U.s. is, yet, the scope of a reimbursement/coverage decision. Although a negative decision past one health plan in the US affects merely coverage of a drug for patients in that one (regional) plan among many, a negative determination in a European land usually applies for the whole public system, i.e., it excludes that pharmaceutical from reimbursement for the entire population; except for those few with individual health insurance. However, there are exceptions in decentralized healthcare systems in Europe, such as in Espana and Italian republic, where a conclusion is only valid for a region or where a centralized determination may be overruled by a region.

Some countries, for example, the UK and until recently Germany do non regulate the manufacturer prices straight and only exert influence on the reimbursement price by ways of health engineering assessment, negotiated rebates, or reference pricing. Other countries, all the same, combine the reimbursement conclusion with statutory pricing or price negotiations, for instance, France, Italy, and Spain. For those countries that regulate prices of pharmaceuticals, information technology is mutual to only regulate prices if manufacturers apply for reimbursement. Also, if a country operates public and private healthcare systems side by side like in Federal republic of germany, regulation of prices may refer to both systems, whereas reimbursement regulation normally refers to only public health insurance.

The reimbursement process normally starts with the manufacturer applying for reimbursement before the launch of their product (eastward.g., France, Italy, and Spain). Exceptions apply, as products may already be sold while the application is being submitted or evaluated (eastward.g., Deutschland and Republic of austria). In some countries, the decision-making procedure is non linked to market launch straight simply may be initiated at any indicate of fourth dimension by the regulator (UK: England). The process itself may include two components (Figure 2):

Figure two. The process of a reimbursement decision.
ane.

A pricing decision past the regulator. Either past (a) an agency/authority that sets list prices, i.e., statutory pricing or (b) by negotiation of listing prices between the manufacturer and an agency/authority.

2.

The reimbursement/coverage decision, i.eastward., the decision on who will get admission to the pharmaceutical (patient population and conditions) and on the amount of reimbursement or the per centum of the list price being reimbursed. Again, the determination may include negotiable (e.g., negotiations on a rebate betwixt the manufacturer and an bureau/authorization on list prices) or nonnegotiable elements.

Both decisions are ordinarily based on some kind of benefit assessment of the pharmaceutical in question. Sorenson (2010) has establish in her comparison that near all the EU countries utilize health engineering cess to some caste to classify pharmaceuticals according to the therapeutic improvement they evangelize. Although the UK applies cost-effectiveness assay directly that results in a Yep/No decision on the reimbursement status of a pharmaceutical for a particular indication, countries such every bit France and Deutschland determine therapeutic improvement (added medical benefit compared with existing therapies) and later on on negotiate rebates or prices in gild to guarantee value for money. According to a systematic literature review by Erntoft (2011) and comparisons of reimbursement decisions by Blankart et al. (2011), other criteria such as budget touch on and type of disease (acute vs. chronic and common vs. orphan) may too play an important part when making reimbursement decisions, especially when deciding on the percentage of list toll that is to be reimbursed. Sometimes, the therapeutic value of a pharmaceutical itself (not in comparison to existing therapies) or the underlying product properties, i.e., whether a drug prolongs life, whether information technology improves, or whether it only maintains the patient's status are used every bit well.

Read full chapter

URL:

https://www.sciencedirect.com/science/commodity/pii/B9780123756787012128

Tissue Expansion

Alex Senchenkov MD , Ernest 1000. Manders MD , in Plastic Surgery Secrets Plus (Second Edition), 2010

33 What will the future bring in the manner of breast reconstruction? Will autogenous tissue reconstruction replace tissue expansion?

As reimbursement for chest reconstruction falls, pressures favoring outpatient reconstruction via soft tissue expansion will mount. Information technology seems probable that the proportion of tissue expansion reconstructions will rise and the number of autogenous tissue reconstructions will autumn. Although some take assessed that the costs of the two approaches were almost the same at their institutions, this has not been our experience. We take found the cost of breast reconstruction with tissue expansion has been half the cost of a transverse rectus abdominis muscle (TRAM) flap. Some insurers provide lower reimbursement for bigger procedures to drive doctors toward less cost-intensive alternatives in reconstructive surgery.

Read full chapter

URL:

https://www.sciencedirect.com/science/commodity/pii/B9780323034708000041

Medical and Health-Related Professions*

Sandy Fritz MS, NCTMB , ... Glenn Yard. Hymel EdD, LMT , in Clinical Massage in the Healthcare Setting, 2008

Health INSURANCE

Reimbursement for services by health insurance companies is common in healthcare. Currently, reliable reimbursement is one of the primary obstacles to inclusion of many complementary methods, such every bit massage. in the healthcare process. This situation likely will improve as more enquiry identifies a positive risk/benefit/price value for massage services to justify healthcare insurance reimbursement.

In the healthcare surround, the infrastructure already exists for billing insurance companies for payment for services rendered. Big facilities, such equally hospitals, have billing departments; small medical practices commonly designate a person to take charge of health insurance billing. In the typical healthcare setting, massage therapists would not be billing directly for services rendered; therefore their responsibility is to make sure that all record-keeping, as well every bit preauthorization treatment plans, are in the patient record. Although some massage therapists bill insurance companies direct in some areas, this is not a mutual exercise. The massage therapist with a career in healthcare needs to empathise enough about health insurance and reimbursement to support the specialist in this area (i.e., the insurance biller and health information management professionals) (Box 3-4).

Wellness insurance is a type of third-political party payer system. This means that the consumer pays for insurance, and when medical expenses occur, the costs are billed and mayhap covered past the insurance. Numerous third-party payers base of operations reimbursements on the allowable charge, which has been influenced by managed care organizations and the authorities. Many forms of health insurance are available. People can buy individual policies, just most get health insurance past being a member of a group that pools its resources to buy the health insurance. Grouping access to wellness insurance may include arrangements such equally employees of a business (often the employer offers health insurance as a benefit); the Bedroom of Commerce, where pocket-sized business owners can obtain coverage; and, for the massage profession, professional associations, such as the American Massage Therapy Association (AMTA) and the Associated Bodywork and Massage Professionals (ABMP). Insurance policies have many coverage options, from minimal coverage to maximum coverage that includes independent nursing facilities, and some at present include alternative and complementary intendance coverage.

Considering of the rising cost of health insurance, a growing number of people do not accept it and therefore do not receive medical care when necessary. Some countries have government-based healthcare. Others have combined processes, in which most people bear some sort of private insurance, and certain at-risk groups, such as children, the poor, and the elderly, are eligible for government programs (east.g., Medicare and Medicaid).

Healthcare in the United States has changed tremendously in contempo years, and the cost of quality healthcare has skyrocketed. Efforts have been made in both the public and individual sectors to introduce various healthcare reforms to contain these costs. Unfortunately, healthcare reform has had little success on the national level; however, land legislatures are beginning to pass laws that have brought improvement. Managed care is a broad term used to depict a diverseness of healthcare plans developed to provide services at a lower cost. Yet, many are dislocated most exactly what managed care entails. Managed intendance has had both positive and negative effects on healthcare delivery.

Massage therapists should become familiar with the major third-party payers, including major medical group insurers, Aetna, United HealthCare, Blue Cross/Blue Shield, Medicaid, Medicare, CHAMPVA, TRICARE, and workers' compensation. Medicare, the largest third-party insurer in the United States, makes quality healthcare affordable for the elderly and other select groups. Medicaid, a joint programme of the federal and state governments, provides healthcare for individuals who authorize for benefits based on income limitations and/or inability (meet Box iii-ii). Workers' compensation covers employees who are injured or who get sick as a result of accidents or adverse conditions in the workplace. Disability programs reimburse individuals for budgetary losses incurred every bit a result of an disability to work for reasons other than those covered under workers' compensation.

Automobile insurance coverage operates in many different means, has different requirements, and may or may non embrace personal injury.

Read full chapter

URL:

https://www.sciencedirect.com/scientific discipline/article/pii/B978032303996350009X

Delivery Paradigm Shifts

David W. CliftonJr. PT , in Physical Rehabilitation's Role in Inability Management, 2005

Image Shift 10: Extenders of Intendance

Reimbursement and health intendance expenditures have led straight to the increased use of extenders of care ( Wilson 1998, Sheppard 1994). These persons have traditionally served in support roles, but under the new prototype they are oft the chief care giver.

The utilise of extenders of care has raised a number of concerns (Robinson et al 1994, Blood & Robinson 1974, Hirsh, 1991). In pure economic terms, extenders are less costly than other licensed professionals. On average they cost 50% to 75% as much equally medical professionals. Rehabilitation employs a growing number and diverseness of extenders, able-bodied trainers, concrete therapist administration, certified occupational therapy administration, practice physiologists, kinesiologists, massage therapists, and strength conditioning coaches. This staffing trend is non without its critics. The widespread use of technicians raises concerns about provider competency, credentials, and clinical outcomes (Salcido, 1996).

Understandably, for some the extender of intendance paradigm is the "son of Frankenstein," just for others it represents an opportunity (Kuchins, 1999).

The growing support of extenders throughout the health care sector is irrefutable, nonetheless. Equally expected, the use of extenders has been most prevalent in rural settings where access to professionals is express (Shi et al, 1993).

Authorities support for this trend is growing, as evidenced by a number of initiatives. At least 1 initiative by the U.S. Department of Education has attempted to develop skill standards for application to health intendance workers beyond the unabridged sector (Salcido, 1996). Additionally, the National Health Intendance Skill Standards Project fosters a collaboration betwixt the health care sector, labor entities, and educational organizations (National Health Care Skill Standards Project, 1995). More 100 major organizations are engaged to develop standards across four service clusters: therapeutic, diagnostic, advisory, and environmental. Rehabilitation professionals are ultimately responsible for whatever and all care that they delegate to others. A number of measures exist that can exist used to optimize the use of extenders of care while minimizing any adverse touch. Refer to Chapter 16 for advice on this and other risk management subjects.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B978072168474150026X

Policy Responses to Uncertainty in Healthcare Resources Allocation Decision Processes

C. McCabe , in Encyclopedia of Health Economics, 2014

Abstract

For reimbursement government charged with protecting and promoting the wellness of the population they serve, the tension between the promise of these new technologies and the relative paucity of bear witness that the hope will exist fulfilled inevitably gives rise to the question 'What if the resources are consumed but the promise is non fulfilled?' Broadly there are 4 strategies for addressing this decision uncertainty: (i) Patient Access Schemes, which focus on achieving patient admission alongside one or more secondary objectives such as per patient price containment, total cost containment, and targeted use or evidence development; (two) Research, which has the reduction of decision incertitude equally its primary objective. This may require that the engineering is not available to patients except as part of the research (only in research (OIR)) or may let admission to the treatment if that does not derange the required inquiry written report or is required for the research to proceed (only with research); (3) Value-based pricing, which sets the price of the engineering at a level that reduces the expected cost of uncertainty associated with reimbursement below the toll of requiring further inquiry; and (iv) Reengineering the prelicensing research and evolution process to meet the needs of reimbursement decision makers. There is great feel with Patient Access Schemes, but the evidence for their value, from a population wellness rather than policy perspective, is express. Formal research as a mechanism for handling decision uncertainty is however in its infancy every bit a practical strategy and likely to exist unpopular with both patients and manufacturers if used more widely. Value-based pricing is conceptually appealing, simply circuitous and possibly non fifty-fifty feasible in practice due to the substantial bear witness capture infrastructure required. Reengineering the prelicensing inquiry and development process to align the prove base with the needs of reimbursement regime may be the long-term solution, but such changes will crave major intellectual and organizational developments in healthcare research, regulation, and reimbursement. Given the timescales that such change requires, the demand for 'band aid' solutions such as patient access and OIR is likely to be a characteristic of the policy landscape for the foreseeable future.

Read full chapter

URL:

https://www.sciencedirect.com/scientific discipline/article/pii/B978012375678701422X

Pharmacogenetics

Janice Y. Chyou , ... Marc S. Sabatine , in Cardiovascular Therapeutics: A Companion to Braunwald'southward Eye Disease (Quaternary Edition), 2013

Toll Effectiveness of Clopidogrel Pharmacogenetics Testing

Universal reimbursement policies for pharmacogenetic testing or platelet function testing for clopidogrel remain to be divers. Although cost may compromise the feasibility and utility of current commercial clopidogrel pharmacogenetic testing, the availability of clopidogrel in generic course in the almost time to come may commencement the price of testing. Furthermore, technological advances and increased availability of testing may shorten the turnaround time, making it easier for test results to be incorporated into clinical decision making. Currently, inexpensive and rapid point-of-care testing has been locally developed and pioneered at several institutions. Formal toll-effectiveness analyses of clopidogrel pharmacogenetic testing will continue to provide useful data.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9781455701018000047